Non-Alcoholic Fatty Liver DiseaseNCT01262326
Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production
A study testing Calorie and Carbohydrate Restriction in people with Non-Alcoholic Fatty Liver Disease, run by University of Texas Southwestern Medical Center at 1 site in United States.
Trial summary
All subjects will be evaluated by the Research Nurse at the Clinical Translational Research Center (CTRC) Outpatient Clinic to obtain informed consent, a brief medical history, weight, body mass index, waist/hip circumference and vital signs. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Non-Alcoholic Fatty Liver Disease
- What is being tested?
- Calorie and Carbohydrate Restriction
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2005to 31 Dec 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- The study will compare sources of hepatic glucose in individuals age 18 to 65 years matched for age, body mass index (BMI), gender, and ethnicity. Enrollment numbers will be higher to accommodate attrition and matching. The genders will be equally represented in both cohorts. The ethnicity of the participants will be chosen to match the general population in the Dallas area. Spanish speaking subjects will be eligible for enrollment. No cultural or ethnic background will be systematically excluded. The present study will be restricted to subjects who are overweight (25>BMI<35). All subjects will have a normal nutritional status and minimal ethanol intake (< 10 g/d). Because activity level is known to alter hepatic metabolism, the subjects chosen will be those who do not participate in regular exercise above the amount of activity associated with daily living. Participation in concurrent studies will be determined on a case-by-case basis. Informed consent will be obtained from all participants.
- The investigators will also enroll subjects diagnosed with NAFLD from Dr. Browning's clinical hepatology practice.
- Based upon the need to study the effects of macronutrient manipulation under a variety of conditions, the targeted enrollment for this protocol will be open-ended. This will allow the present application to act as the basis for studying hepatic metabolism under a variety of conditions. The enrollment target is 80 subjects.
Who cannot join
- In order to eliminate confounding variables, the participants chosen will have to be in stable health, on no medications known to alter hepatic glucose metabolism, on no weight loss diet or diet pills within the previous 6 months, and without baseline ketonuria. The present study will be restricted to subjects who are overweight (25>BMI<35). Subjects with a history of renal calculi, gout/hyperuricemia, renal insufficiency, will also be excluded from the study. Pregnant women, children, and institutionalized individuals will also be excluded. NAFLD subjects with metal in or on their body will be excluded.
Trial locations and contacts
1 site in 1 country.
About this study
All subjects will be evaluated by the Research Nurse at the Clinical Translational Research Center (CTRC) Outpatient Clinic to obtain informed consent, a brief medical history, weight, body mass index, waist/hip circumference and vital signs. Additionally, blood will be drawn at this visit to screen for renal dysfunction (Chem 10), liver disease (liver function tests (LFT's)), thyroid dysfunction (TSH), diabetes mellitus (HbA1C), and chronic inflammatory states (erythrocyte sedimentation rate). Subjects recruited to the study will be placed on a low-carbohydrate diet (<20 g/d without caloric restriction) designed either to promote weight loss or maintain weight stability for fourteen days prior to the protocol or they will consume a typical "Western" diet designed either to promote weight loss (restricted by 1300 kcal/d in the final fourteen days) or maintain weight stability for twenty-one days. Subjects recruited to the study will be lean, overweight, or obese and also may carry a diagnosis of NAFLD. Target accrual for total enrollment for this project will be set to 80 subjects to accommodate attrition and screen failures. The details of the low-carbohydrate diet have been discussed in consultation with Linda Brinkley, nutrition staff of the CTRC. Subjects chosen to undergo carbohydrate-restriction will have a teaching session with a CTRC dietician. Subjects will then initiate dietary carbohydrate-restriction on their own and keep a daily dietary record for seven days. At the end of seven days, the dietary record will be analyzed. The CTRC will then prepare all meals for the final seven days of the diet in accordance with daily caloric intake calculated from the dietary record. Calorie-restricted participants will keep a dietary record for one week while eating a typical "Western" diet. The dietician will analyze this record and meals restricted by 1300 kcal/d will be prepared by the CTRC for the final fourteen days of the diet. Alternatively, some subjects eating a typical "Western" diet may consume prepared meals with a fixed content of carbohydrate, fat, and protein that is unrelated to their pre-study dietary intake. In this scenario, the dietary carbohydrate content may be varied between 30 and 60% to provide information on differences in hepatic metabolism under conditions of differing, but clinically sustainable, carbohydrate intake. All participants will be admitted to the CTRC the night prior to the study and begin an overnight fast after dinner. Between 18:00 and 09:00, subjects will receive two stable isotope tracers orally: [U-13C]propionate at 08:00 (three 400 mg doses given over 1 hour) and 70% 2H2O at 22:00, 02:00, and 06:00. During the study subjects will also be given 0.5% 2H2O ad libitum. Two 500 mg acetaminophen tablets will also be given at 08:00. Between 08:00 and 09:00 subjects will undergo measurement of their respiratory quotient (RQ) using the CTRC indirect calorimeter (Delta Trac II).. Subjects will then have an intravenous catheter placed and an infusion of tracer amounts of [3,4-13C2]glucose, [1,2-13C]β-hydroxybutyrate and [3,4-13C]acetoacetate will be initiated. At 1 ½ and 2 hours after initiation of the infusion, a 50 cc blood draw will be performed. Voided urine will be collected every hour after ingestion of acetaminophen until the protocol concludes. The subject will then be given a meal and discharged from the CTRC, marking the completion of the protocol. The collected blood and urine will be transported by the research coordinator to the Advanced Imaging Research Center lab for analysis by MRS. Another blood draw (approximately 10 cc) will be done in conjunction with the final MRI in order to measure changes in the lipid profile after the diet intervention. The visits in their entirety will be as follows:
1 screening visit: 20 minutes
Read more
- dietician visit: 20 minutes
- MRS visits: 45 minutes each
1 (optional) overnight visit: 20 hours
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Being tested
- Calorie and Carbohydrate Restriction
- Medical subject headings
- Non-alcoholic Fatty Liver Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Calorie and Carbohydrate RestrictionOther
Carbohydrate Restriction = <20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
| Study group | Role | What they receive |
|---|---|---|
| Low Carbohydrate Diet | Experimental | Subjects are placed on a low carbohydrate diet where only 5% of energy intake is derived from dietary carbohydrate. Receives: Other: Calorie and Carbohydrate Restriction |
| Low Calorie Diet | Active comparator | Subjects have there caloric intake reduced to 1200 or 1500 kcal/day (women and men respectively). Receives: Other: Calorie and Carbohydrate Restriction |
What is being measured
The primary outcome is the main question the study is designed to answer.
Liver triglyceride content
Measured: 2 weeks
Secondary outcomes (1)
Measures of hepatic and whole-body oxidation
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2010 (estimated)
- Study startJan 2005
- Primary completion31 Dec 2011
- Study completion31 Dec 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Non-Alcoholic Fatty Liver DiseaseStudies of the same condition, open and under way.
- More trials run by University of Texas Southwestern Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jeffrey Browning, University of Texas Southwestern Medical Center
- Investigators
- Jeffrey D Browning, MD, Principal investigator, University of Texas Southwestern Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01262326
- Sponsor's protocol ID
- 012005-053
- Status last verified
- Nov 2018
- First submitted
- 15 Dec 2010
- Last updated
- 16 Nov 2018
- Results posted
- No
Publications
Browning JD, Weis B, Davis J, Satapati S, Merritt M, Malloy CR, Burgess SC. Alterations in hepatic glucose and energy metabolism as a result of calorie and carbohydrate restriction. Hepatology. 2008 Nov;48(5):1487-96. doi: 10.1002/hep.22504.
PubMed 18925642Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011 May;93(5):1048-52. doi: 10.3945/ajcn.110.007674. Epub 2011 Mar 2.
PubMed 21367948
Study at a glance
From the registry record, last updated by the sponsor on 16 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production
- ClinicalTrials.gov ID
- NCT01262326
- Acronym / sponsor ID
- 012005-053
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- University of Texas Southwestern Medical CenterUniversity, hospital or other
- Study start
- Jan 2005
- Primary completion
- 31 Dec 2011 (actual)
- Study completion
- 31 Dec 2011 (actual)
- First posted
- 17 Dec 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
All subjects will be evaluated by the Research Nurse at the Clinical Translational Research Center (CTRC) Outpatient Clinic to obtain informed consent, a brief medical history, weight, body mass index, waist/hip circumference and vital signs. Additionally, blood will be drawn at this visit to screen for renal dysfunction (Chem 10), liver disease (liver function tests (LFT's)), thyroid dysfunction (TSH), diabetes mellitus (HbA1C), and chronic inflammatory states (erythrocyte sedimentation rate). Subjects recruited to the study will be placed on a low-carbohydrate diet (<20 g/d without caloric restriction) designed either to promote weight loss or maintain weight stability for fourteen days prior to the protocol or they will consume a typical "Western" diet designed either to promote weight loss (restricted by 1300 kcal/d in the final fourteen days) or maintain weight stability for twenty-one days. Subjects recruited to the study will be lean, overweight, or obese and also may carry a diagnosis of NAFLD. Target accrual for total enrollment for this project will be set to 80 subjects to accommodate attrition and screen failures. The details of the low-carbohydrate diet have been discussed in consultation with Linda Brinkley, nutrition staff of the CTRC. Subjects chosen to undergo carbohydrate-restriction will have a teaching session with a CTRC dietician. Subjects will then initiate dietary carbohydrate-restriction on their own and keep a daily dietary record for seven days. At the end of seven days, the dietary record will be analyzed. The CTRC will then prepare all meals for the final seven days of the diet in accordance with daily caloric intake calculated from the dietary record. Calorie-restricted participants will keep a dietary record for one week while eating a typical "Western" diet. The dietician will analyze this record and meals restricted by 1300 kcal/d will be prepared by the CTRC for the final fourteen days of the diet. Alternatively, some subjects eating a typical "Western" diet may consume prepared meals with a fixed content of carbohydrate, fat, and protein that is unrelated to their pre-study dietary intake. In this scenario, the dietary carbohydrate content may be varied between 30 and 60% to provide information on differences in hepatic metabolism under conditions of differing, but clinically sustainable, carbohydrate intake. All participants will be admitted to the CTRC the night prior to the study and begin an overnight fast after dinner. Between 18:00 and 09:00, subjects will receive two stable isotope tracers orally: [U-13C]propionate at 08:00 (three 400 mg doses given over 1 hour) and 70% 2H2O at 22:00, 02:00, and 06:00. During the study subjects will also be given 0.5% 2H2O ad libitum. Two 500 mg acetaminophen tablets will also be given at 08:00. Between 08:00 and 09:00 subjects will undergo measurement of their respiratory quotient (RQ) using the CTRC indirect calorimeter (Delta Trac II).. Subjects will then have an intravenous catheter placed and an infusion of tracer amounts of [3,4-13C2]glucose, [1,2-13C]β-hydroxybutyrate and [3,4-13C]acetoacetate will be initiated. At 1 ½ and 2 hours after initiation of the infusion, a 50 cc blood draw will be performed. Voided urine will be collected every hour after ingestion of acetaminophen until the protocol concludes. The subject will then be given a meal and discharged from the CTRC, marking the completion of the protocol. The collected blood and urine will be transported by the research coordinator to the Advanced Imaging Research Center lab for analysis by MRS. Another blood draw (approximately 10 cc) will be done in conjunction with the final MRI in order to measure changes in the lipid profile after the diet intervention. The visits in their entirety will be as follows:
1 screening visit: 20 minutes
- dietician visit: 20 minutes
- MRS visits: 45 minutes each
1 (optional) overnight visit: 20 hours
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Low Carbohydrate Diet | Experimental | Other: Calorie and Carbohydrate RestrictionSubjects are placed on a low carbohydrate diet where only 5% of energy intake is derived from dietary carbohydrate. |
| Low Calorie Diet | Active comparator | Other: Calorie and Carbohydrate RestrictionSubjects have there caloric intake reduced to 1200 or 1500 kcal/day (women and men respectively). |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- The study will compare sources of hepatic glucose in individuals age 18 to 65 years matched for age, body mass index (BMI), gender, and ethnicity. Enrollment numbers will be higher to accommodate attrition and matching. The genders will be equally represented in both cohorts. The ethnicity of the participants will be chosen to match the general population in the Dallas area. Spanish speaking subjects will be eligible for enrollment. No cultural or ethnic background will be systematically excluded. The present study will be restricted to subjects who are overweight (25>BMI<35). All subjects will have a normal nutritional status and minimal ethanol intake (< 10 g/d). Because activity level is known to alter hepatic metabolism, the subjects chosen will be those who do not participate in regular exercise above the amount of activity associated with daily living. Participation in concurrent studies will be determined on a case-by-case basis. Informed consent will be obtained from all participants.
- The investigators will also enroll subjects diagnosed with NAFLD from Dr. Browning's clinical hepatology practice.
- Based upon the need to study the effects of macronutrient manipulation under a variety of conditions, the targeted enrollment for this protocol will be open-ended. This will allow the present application to act as the basis for studying hepatic metabolism under a variety of conditions. The enrollment target is 80 subjects.
Key exclusion criteria (1 listed)
- In order to eliminate confounding variables, the participants chosen will have to be in stable health, on no medications known to alter hepatic glucose metabolism, on no weight loss diet or diet pills within the previous 6 months, and without baseline ketonuria. The present study will be restricted to subjects who are overweight (25>BMI<35). Subjects with a history of renal calculi, gout/hyperuricemia, renal insufficiency, will also be excluded from the study. Pregnant women, children, and institutionalized individuals will also be excluded. NAFLD subjects with metal in or on their body will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Calorie and Carbohydrate RestrictionCarbohydrate Restriction = <20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men | Other | Low Calorie Diet, Low Carbohydrate Diet |
Primary outcome
Liver triglyceride content
Time frame: 2 weeks
1 secondary outcome
Measures of hepatic and whole-body oxidation
Time frame: 2 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Nov 2018.
- Results publication: PubMed 18925642Browning JD, Weis B, Davis J, Satapati S, Merritt M, Malloy CR, Burgess SC. Alterations in hepatic glucose and energy metabolism as a result of calorie and carbohydrate restriction. Hepatology. 2008 Nov;48(5):1487-96. doi: 10.1002/hep.22504.
- Derived from this study: PubMed 21367948Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011 May;93(5):1048-52. doi: 10.3945/ajcn.110.007674. Epub 2011 Mar 2.
Related trials for Non-Alcoholic Fatty Liver Disease
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Recruiting
NAFLD Clinical Care Pathway
NAFLD, MASLD
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
RecruitingPhase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-alcoholic Fatty Liver Disease
RecruitingPhase 2
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jeffrey D Browning, MD principal investigator
University of Texas Southwestern Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Calorie and Carbohydrate Restriction in people with Non-Alcoholic Fatty Liver Disease, run by University of Texas Southwestern Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Liver triglyceride content (time frame: 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01262326, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Nov 2018.